Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2005 1
2006 1
2007 1
2008 2
2009 1
2010 1
2012 2
2013 2
2014 3
2016 1
2017 1
2018 1
2019 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Martínez C, et al. J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28. J Clin Oncol. 2017. PMID: 28846465 Free article.
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor ( …
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidenti …
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N; Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Kyriakou C, et al. J Clin Oncol. 2008 Jan 10;26(2):218-24. doi: 10.1200/JCO.2008.12.6219. J Clin Oncol. 2008. PMID: 18182664
PURPOSE: Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with …
PURPOSE: Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim …
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation.
Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G; Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation. Miano M, et al. Bone Marrow Transplant. 2007 Jan;39(2):89-99. doi: 10.1038/sj.bmt.1705550. Bone Marrow Transplant. 2007. PMID: 17213848
The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseas …
The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia re …
The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma.
Sureda A, Pereira MI, Dreger P; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Sureda A, et al. Curr Opin Oncol. 2012 Nov;24(6):727-32. doi: 10.1097/CCO.0b013e328359557e. Curr Opin Oncol. 2012. PMID: 23079783 Review.
PURPOSE OF REVIEW: Autologous stem cell transplantation (ASCT) represents the treatment of choice for primary refractory or relapsed Hodgkin's lymphoma patients. Nevertheless, the results of ASCT are not universally uniform in all groups of patients. ...Outcome of multiply …
PURPOSE OF REVIEW: Autologous stem cell transplantation (ASCT) represents the treatment of choice for primary refractory or relapsed Hodgkin …
Late complications after hematopoietic stem cell transplantation.
Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, Socié G; Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Tichelli A, et al. Expert Rev Hematol. 2009 Oct;2(5):583-601. doi: 10.1586/ehm.09.48. Expert Rev Hematol. 2009. PMID: 21083023 Review.
Hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure to patients with leukemia, lymphoma and severe non-malignant diseases. More than 40,000 HSCTs are performed annually worldwide. ...
Hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure to patients with leukemia, lymphoma and severe non-mal …
Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency.
Aydin SE, Freeman AF, Al-Herz W, Al-Mousa HA, Arnaout RK, Aydin RC, Barlogis V, Belohradsky BH, Bonfim C, Bredius RG, Chu JI, Ciocarlie OC, Doğu F, Gaspar HB, Geha RS, Gennery AR, Hauck F, Hawwari A, Hickstein DD, Hoenig M, Ikinciogullari A, Klein C, Kumar A, Ifversen MRS, Matthes S, Metin A, Neven B, Pai SY, Parikh SH, Picard C, Renner ED, Sanal Ö, Schulz AS, Schuster F, Shah NN, Shereck EB, Slatter MA, Su HC, van Montfrans J, Woessmann W, Ziegler JB, Albert MH; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and the European Society for Primary Immunodeficiencies. Aydin SE, et al. J Allergy Clin Immunol Pract. 2019 Mar;7(3):848-855. doi: 10.1016/j.jaip.2018.10.035. Epub 2018 Nov 2. J Allergy Clin Immunol Pract. 2019. PMID: 30391550 Free PMC article.
Causes of death were infections (n = 5), graft versus host disease (5), multiorgan failure (2), and preexistent lymphoma (1). Survival after matched related (n = 40) or unrelated (35) HSCT was 89% and 81%, respectively. ...
Causes of death were infections (n = 5), graft versus host disease (5), multiorgan failure (2), and preexistent lymphoma (1). Surviva …
Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation.
Ringdén O, Labopin M, Gorin NC, Volin L, Torelli GF, Attal M, Jouet JP, Milpied N, Socié G, Cordonnier C, Michallet M, Atienza AI, Hermine O, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O, et al. Br J Haematol. 2012 Apr;157(2):220-9. doi: 10.1111/j.1365-2141.2012.09034.x. Epub 2012 Feb 2. Br J Haematol. 2012. PMID: 22299728 Free article. Clinical Trial.
The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, Colombat P, Biron P, Tilly H, Pfreundschuh M, Cordonnier C, Sureda A, Cahn JY, Vernant JP, Gribben J, Cook G, Haynes AP, Ferrant A, Finel H, Montoto S, Dreger P; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). El-Najjar I, et al. Ann Oncol. 2014 Nov;25(11):2224-2229. doi: 10.1093/annonc/mdu440. Epub 2014 Sep 5. Ann Oncol. 2014. PMID: 25193988 Free article.
BACKGROUND: The aim of this study was to investigate the impact of the high-dose regimen on the outcome of patients with follicular lymphoma (FL) having had autologous stem-cell transplantation (ASCT) in a recent time period. ...
BACKGROUND: The aim of this study was to investigate the impact of the high-dose regimen on the outcome of patients with follicular lymph …
Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.
Rocha V, Ruggeri A, Spellman S, Wang T, Sobecks R, Locatelli F, Askar M, Michel G, Arcese W, Iori AP, Purtill D, Danby R, Sanz GF, Gluckman E, Eapen M; Eurocord, Cord Blood Committee Cellular Therapy Immunobiology Working Party of the European Group for Blood and Marrow Transplantation, Netcord, and the Center for International Blood and Marrow Transplant Research. Rocha V, et al. Biol Blood Marrow Transplant. 2016 Jul;22(7):1284-1289. doi: 10.1016/j.bbmt.2016.04.007. Epub 2016 Apr 16. Biol Blood Marrow Transplant. 2016. PMID: 27090957 Free PMC article.
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Kröger N, et al. Bone Marrow Transplant. 2006 Jan;37(2):183-9. doi: 10.1038/sj.bmt.1705226. Bone Marrow Transplant. 2006. PMID: 16299545
The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3). ...
The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leuke …
18 results